Calcium and Bone Metabolism: Pathophysiology and Molecular Mechanisms

Calcium homeostasis is a tightly regulated process essential for numerous physiological functions including muscle contraction, nerve transmission, blood coagulation, and bone mineralization. The normal serum calcium range is 2.2-2.6 mmol/L (8.8-10.4 mg/dL), with approximately 50% bound to albumin, 40% ionized (physiologically active), and 10% complexed with anions.

Three primary hormones regulate calcium homeostasis: parathyroid hormone (PTH), calcitriol (1,25-dihydroxyvitamin D₃), and calcitonin. PTH is synthesized as a 115-amino acid precursor (pre-proPTH) in parathyroid chief cells, processed to an 84-amino acid mature hormone stored in secretory vesicles. The calcium-sensing receptor (CaSR), a G-protein coupled receptor on parathyroid cells, detects ionized calcium changes and inversely regulates PTH secretion through a negative feedback mechanism.

PTH exerts its effects through the PTH receptor (PTHR1), a Gs-coupled receptor that activates adenylyl cyclase, increasing cAMP levels. In kidneys, PTH promotes calcium reabsorption in the distal convoluted tubule via TRPV5 channels and stimulates 1α-hydroxylase activity in proximal tubules, converting 25-hydroxyvitamin D₃ to active calcitriol. In bone, PTH has dual effects: acute administration promotes osteoblast activity and bone formation, while chronic elevation stimulates osteoclast-mediated bone resorption through RANKL upregulation.

Vitamin D metabolism begins with 7-dehydrocholesterol conversion to cholecalciferol (vitamin D₃) in skin upon UVB exposure. Sequential hydroxylations occur: 25-hydroxylation in liver by CYP2R1 and CYP27A1, then 1α-hydroxylation in kidneys by CYP27B1 to form active calcitriol. The vitamin D receptor (VDR) is a nuclear receptor that, upon calcitriol binding, forms heterodimers with retinoid X receptor (RXR) and regulates gene transcription. Calcitriol enhances intestinal calcium absorption through calbindin-D induction and promotes phosphate absorption via sodium-phosphate cotransporters.

Hypercalcemia, defined as serum calcium >2.6 mmol/L (>10.4 mg/dL), results from increased bone resorption, enhanced intestinal absorption, or decreased renal excretion. Primary hyperparathyroidism and malignancy account for >90% of cases, with the mnemonic "groans, stones, bones, and psychiatric overtones" describing classic symptoms.

Primary hyperparathyroidism most commonly results from parathyroid adenomas (80-85%), followed by hyperplasia (10-15%) and rarely carcinoma (<1%). Adenomas typically involve single gland enlargement with suppressed function in remaining glands. Multiple endocrine neoplasia (MEN) syndromes should be considered in familial cases or multiple gland involvement. MEN1 involves parathyroid hyperplasia with pancreatic islet cell tumors and pituitary adenomas, while MEN2A includes parathyroid hyperplasia with medullary thyroid carcinoma and pheochromocytoma.

Malignancy-associated hypercalcemia occurs through two mechanisms: humoral hypercalcemia of malignancy (HHM) and osteolytic metastases. HHM, accounting for 80% of malignancy-related cases, involves PTH-related peptide (PTHrP) secretion by tumors. PTHrP shares structural homology with PTH's N-terminal region and activates the same PTHR1 receptor, causing increased renal calcium reabsorption and bone resorption while suppressing PTH secretion. Common PTHrP-secreting tumors include squamous cell carcinomas, renal cell carcinoma, and breast cancer.

Osteolytic metastases directly destroy bone matrix, releasing calcium. Breast cancer, lung cancer, kidney cancer, and multiple myeloma commonly cause osteolytic lesions. Cytokines including RANKL, IL-6, and TNF-α promote osteoclast activation and bone resorption. Multiple myeloma uniquely produces dickkopf-1 (DKK1), inhibiting Wnt signaling and suppressing osteoblast function while enhancing osteoclast activity.

Other hypercalcemia causes include granulomatous diseases (sarcoidosis, tuberculosis) where activated macrophages express extra-renal 1α-hydroxylase, producing calcitriol independent of PTH regulation. Milk-alkali syndrome from excessive calcium and absorbable alkali intake causes hypercalcemia with metabolic alkalosis and renal insufficiency.

Hypocalcemia, defined as serum calcium <2.2 mmol/L (<8.8 mg/dL), manifests primarily through neuromuscular hyperexcitability due to decreased membrane threshold potential. Clinical signs include Chvostek's sign (facial muscle twitching upon tapping facial nerve) and Trousseau's sign (carpopedal spasm during blood pressure cuff inflation), paresthesias, tetany, and potentially life-threatening laryngospasm or seizures.

Hypoparathyroidism represents the most common cause, resulting from surgical removal during thyroidectomy, autoimmune destruction, or congenital absence. DiGeorge syndrome involves 22q11.2 deletion causing absent or hypoplastic parathyroid glands and thymus, leading to hypoparathyroidism and T-cell immunodeficiency. Autoimmune polyendocrinopathy syndrome type 1 (APS-1) involves mutations in the AIRE gene, causing chronic mucocutaneous candidiasis, hypoparathyroidism, and adrenal insufficiency.

Pseudohypoparathyroidism (PHP) encompasses disorders of PTH resistance rather than deficiency. PHP type 1a results from GNAS gene mutations affecting the Gα subunit of G-proteins, causing resistance to multiple hormones including PTH, TSH, and gonadotropins. Patients exhibit Albright hereditary osteodystrophy phenotype: short stature, round face, brachydactyly, and subcutaneous calcifications. PHP type 1b involves selective PTH resistance due to methylation defects affecting GNAS expression specifically in target tissues.

Vitamin D deficiency or resistance causes hypocalcemia through decreased intestinal calcium absorption. Rickets in children and osteomalacia in adults result from inadequate mineralization of bone matrix. Vitamin D-dependent rickets type 1 involves 1α-hydroxylase deficiency (CYP27B1 mutations), preventing calcitriol formation. Type 2 rickets results from VDR mutations causing calcitriol resistance despite elevated levels.

Magnesium deficiency impairs PTH secretion and creates PTH resistance, causing functional hypoparathyroidism. Magnesium is required for PTH synthesis and release, and hypomagnesemia must be corrected before hypocalcemia resolves. Acute pancreatitis can cause hypocalcemia through fatty acid soap formation and cytokine-mediated PTH resistance.

Osteoporosis is characterized by decreased bone mass and microarchitectural deterioration, leading to increased fracture risk. Bone mineral density (BMD) T-scores ≤-2.5 standard deviations below young adult peak define osteoporosis, while scores between -1.0 and -2.5 indicate osteopenia. The World Health Organization criteria apply to postmenopausal women and men >50 years.

Bone remodeling involves coupled bone resorption by osteoclasts and formation by osteoblasts, maintaining skeletal integrity. Peak bone mass is achieved by age 30, followed by gradual decline of 0.5-1% annually. Postmenopausal women experience accelerated bone loss (2-5% annually) due to estrogen deficiency affecting the RANK/RANKL/OPG pathway. Estrogen normally suppresses RANKL expression and enhances OPG production by osteoblasts, limiting osteoclast activation.

Osteoclast differentiation requires RANKL binding to RANK receptors on osteoclast precursors, activating NF-κB and other transcription factors. Osteoprotegerin (OPG) acts as a decoy receptor, sequestering RANKL and preventing osteoclast activation. The RANKL/OPG ratio determines bone resorption rates. Estrogen deficiency increases this ratio, promoting bone resorption. Additionally, estrogen deficiency enhances osteoclast lifespan through decreased apoptosis and reduces osteoblast function.

Secondary osteoporosis results from underlying conditions or medications. Glucocorticoid-induced osteoporosis represents the most common secondary form, occurring through multiple mechanisms: decreased osteoblast proliferation and function, increased osteoblast and osteocyte apoptosis, reduced intestinal calcium absorption, increased renal calcium excretion, and indirect effects through reduced sex hormone production. Glucocorticoids also promote osteoclast activation and extend osteoclast lifespan.

Other secondary causes include hyperparathyroidism (chronic PTH elevation promoting bone resorption), hyperthyroidism (increased bone turnover), chronic kidney disease (secondary hyperparathyroidism and vitamin D deficiency), malabsorption syndromes, and medications including anticonvulsants, proton pump inhibitors, and aromatase inhibitors. Lifestyle factors such as smoking, excessive alcohol consumption, physical inactivity, and inadequate calcium/vitamin D intake contribute to osteoporosis development.

Paget disease of bone is a focal disorder of bone remodeling characterized by excessive, disorganized bone turnover leading to enlarged, weakened bones. The disease progresses through three phases: initial osteolytic phase with increased bone resorption, mixed osteolytic-osteoblastic phase, and final osteosclerotic phase with predominantly bone formation. The pathognomonic finding is the mosaic pattern of lamellar bone on histology.

The etiology involves both genetic and environmental factors. Mutations in several genes have been identified, with SQSTM1 (sequestosome 1) mutations being most common, accounting for 10-50% of familial cases. SQSTM1 encodes p62, a scaffold protein involved in autophagy and NF-κB signaling. Mutant p62 leads to enhanced osteoclast activation through increased NF-κB activity and resistance to apoptosis. Other mutations include TNFRSF11A (encoding RANK), TNFRSF11B (encoding OPG), and genes affecting autophagy pathways.

Viral etiology has been proposed, with paramyxovirus-like inclusion bodies identified in pagetic osteoclasts. These inclusions contain nucleocapsid proteins resembling measles virus, respiratory syncytial virus, or canine distemper virus. However, viral RNA has not been consistently detected, and the viral hypothesis remains controversial. Current evidence suggests viral infection may trigger disease in genetically susceptible individuals.

Pagetic osteoclasts are characteristically enlarged, containing 10-100 nuclei compared to 3-5 in normal osteoclasts. These multinucleated giant cells demonstrate increased bone resorption capacity and resistance to apoptosis. The excessive bone resorption stimulates compensatory osteoblast activity, but the newly formed bone is structurally abnormal, disorganized, and mechanically inferior to normal lamellar bone.

Clinical manifestations depend on disease location and extent. Bone pain is most common, often described as deep, aching, and worse at night. Deformities include bowing of long bones, skull enlargement, and spinal kyphosis. Complications include pathologic fractures (often transverse "chalk-stick" fractures), osteoarthritis of adjacent joints, nerve compression (especially eighth cranial nerve causing hearing loss), and rarely, osteosarcoma development (1% risk). High-output heart failure can occur in extensive disease due to increased bone vascularity.

Laboratory assessment of calcium and bone metabolism requires understanding of various biomarkers reflecting bone turnover, mineral homeostasis, and underlying pathophysiology. Serum calcium measurement should be corrected for albumin levels using the formula: corrected calcium = measured calcium + 0.8 × (40 - albumin g/L). Ionized calcium provides the most accurate assessment of calcium status but requires careful sample handling.

Parathyroid hormone levels must be interpreted in context of serum calcium. Intact PTH assays measure the biologically active 1-84 amino acid hormone, with normal range 1.3-6.8 pmol/L (12-65 pg/mL). Primary hyperparathyroidism shows elevated or inappropriately normal PTH with hypercalcemia, while secondary hyperparathyroidism demonstrates elevated PTH with normal or low calcium. PTH-independent hypercalcemia (malignancy, granulomatous disease) suppresses PTH to undetectable levels.

Vitamin D status is assessed through 25-hydroxyvitamin D₃ [25(OH)D₃] levels, reflecting total body vitamin D stores. Optimal levels are >75 nmol/L (>30 ng/mL), with deficiency defined as <50 nmol/L (<20 ng/mL). 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃] has a short half-life and doesn't reflect vitamin D status but may be elevated in granulomatous diseases due to extra-renal 1α-hydroxylase activity.

Bone formation markers include osteocalcin, bone-specific alkaline phosphatase (BSAP), and procollagen type I N-terminal propeptide (P1NP). Osteocalcin is synthesized exclusively by osteoblasts and reflects bone formation rate. P1NP is released during collagen type I synthesis and correlates well with histomorphometric bone formation parameters. Total alkaline phosphatase elevation may indicate bone disease but lacks specificity.

Bone resorption markers include C-terminal telopeptide of type I collagen (CTX) and N-terminal telopeptide (NTX), reflecting collagen breakdown products released during bone resorption. These markers show circadian variation with peaks in early morning and should be measured in fasting state. Tartrate-resistant acid phosphatase (TRAP) 5b is specifically produced by osteoclasts and reflects osteoclast number and activity.

Paget disease characteristically shows markedly elevated alkaline phosphatase, often 10-25 times normal, reflecting increased bone formation. The degree of elevation correlates with disease extent and activity. Urinary hydroxyproline, reflecting collagen breakdown, may also be elevated but is less specific than modern collagen cross-link markers.

Understanding the molecular mechanisms of calcium and bone metabolism enables targeted therapeutic interventions for metabolic bone diseases. Treatment strategies aim to restore normal bone turnover, correct mineral imbalances, and prevent complications such as fractures.

Bisphosphonates represent the cornerstone of osteoporosis and Paget disease treatment. These pyrophosphate analogs bind to hydroxyapatite crystals in bone and are internalized by osteoclasts during bone resorption. Nitrogen-containing bisphosphonates (alendronate, risedronate, zoledronic acid) inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, preventing protein prenylation essential for osteoclast function. This leads to osteoclast apoptosis and decreased bone resorption.

Non-nitrogen bisphosphonates (etidronate, clodronate) are metabolized to toxic ATP analogs that induce osteoclast apoptosis. Bisphosphonates have long skeletal half-lives (>10 years), enabling infrequent dosing but raising concerns about oversuppression of bone turnover and atypical fractures with long-term use.

Denosumab, a fully human monoclonal antibody against RANKL, provides an alternative mechanism for osteoporosis treatment. By binding RANKL, denosumab prevents RANK activation and osteoclast formation, function, and survival. Unlike bisphosphonates, denosumab effects are rapidly reversible upon discontinuation, requiring consideration of rebound bone loss and fracture risk.

Teriparatide, a synthetic PTH analog containing amino acids 1-34, represents the only anabolic bone therapy currently available. Intermittent PTH administration promotes osteoblast proliferation, reduces osteoblast apoptosis, and stimulates bone formation. The anabolic window occurs within 4-6 hours of injection, after which catabolic effects predominate. Treatment duration is limited to 24 months due to osteosarcoma concerns in animal studies.

Calcium and vitamin D supplementation form the foundation of bone health maintenance. Recommended calcium intake is 1000-1200 mg daily for adults, with vitamin D₃ (cholecalciferol) preferred over vitamin D₂ (ergocalciferol) due to superior bioavailability and longer half-life. Active vitamin D analogs (calcitriol, paricalcitol) may be required in chronic kidney disease patients with impaired 1α-hydroxylase activity.

Treatment of hypercalcemia depends on severity and underlying cause. Bisphosphonates effectively treat malignancy-associated hypercalcemia by inhibiting bone resorption, with zoledronic acid preferred for its potency and convenient dosing. Calcitonin provides rapid but temporary calcium reduction through inhibition of osteoclast activity and increased renal calcium excretion.